Accuracy of Post–Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer-Reference-Cited by-同舟云学术

Accuracy of Post–Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer

Published:2020-12-16 Issue:12 Volume:155 Page:e204103
ISSN:2168-6254
Container-title:JAMA Surgery
language:en
Short-container-title:JAMA Surg

Author:

Tasoulis Marios Konstantinos¹,Lee Han-Byoel²³⁴,Yang Wei⁵,Pope Romney⁶,Krishnamurthy Savitri⁷,Kim Soo-Yeon⁸,Cho Nariya⁸,Teoh Victoria¹,Rauch Gaiane M.⁹,Smith Benjamin D.¹⁰,Valero Vicente¹¹,Mohammed Kabir¹²,Han Wonshik²³⁴,MacNeill Fiona¹,Kuerer Henry M.¹³

Affiliation:

1. Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom

2. Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea

3. Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea

4. Cancer Research Institute, Seoul National University, Seoul, South Korea

5. Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston

6. Department of Radiology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

7. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston

8. Department of Radiology, Seoul National University Hospital, Seoul, South Korea

9. Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston

10. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston

11. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston

12. Research and Development Department, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

13. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Surgery

Link

https://jamanetwork.com/journals/jamasurgery/articlepdf/2771053/jamasurgery_tasoulis_2020_oi_200066_1608067497.5846.pdf

Reference23 articles.

1. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.;Killelea;J Am Coll Surg,2015

2. Adjuvant capecitabine for breast cancer after preoperative chemotherapy.;Masuda;N Engl J Med,2017

3. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.;von Minckwitz;N Engl J Med,2019

4. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).;Sikov;J Clin Oncol,2015

5. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).;Schneeweiss;Ann Oncol,2013

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression;Molecular Oncology;2024-06-12

2. A nomogram to predict the pathological complete response in patients with breast cancer based on the TILs-US score;Japanese Journal of Clinical Oncology;2024-06-12

3. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy;European Journal of Surgical Oncology;2024-06

4. Omission of Breast Surgery in Exceptional Responders;Clinical Breast Cancer;2024-06

5. A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012);Frontiers in Oncology;2024-05-10